Abstract
Background While associations of antibiotic resistance traits are not random in multidrug-resistant (MDR) bacteria, clinically relevant resistance patterns remain relatively underexplored. This study used machine learning, specifically association-set mining, to explore resistance associations within E. coli isolates from community-acquired urinary tract infections (UTIs).
Methods We analysed antibiograms of community-acquired E. coli UTI isolates collected from 2018 to 2022 by France’s national surveillance system. Association-set mining was applied separately to extended-spectrum beta-lactamase-producing E. coli (ESBL-EC) and non-ESBL-EC. MDR patterns that had expected support (reflecting pattern frequency) and conditional lift (reflecting association strength) higher than expected by chance (p-value≤0.05) were used to construct resistance networks, and analysed according to time, age and gender.
Findings The number of isolates increased from 360 287 in 2018 (10 150 ESBL-EC, 350 137 non-ESBL-EC) to 629 017 in 2022 (18 663 ESBL-EC, 610 354 non-ESBL-EC). More MDR patterns were selected in ESBL-EC than non-ESBL-EC (2022: 1770 vs 93 patterns), with higher respective network densities (2022: 0.230 vs 0.074). Fluoroquinolone, third-generation cephalosporin and penicillin resistances were strongly associated in ESBL-EC. The median densities of resistance association networks increased from 2018 to 2022 in both ESBL-EC (0.238 to 0.302, p-value=0.06, Pearson test) and non-ESBL-EC (0.074 to 0.100, p-value=0.04). Across all years, median network densities were higher in men than women in both ESBL-EC (2022: 0.305 vs 0.276) and non-ESBL-EC (2022: 0.128 vs 0.094); they were also higher in individuals over 65 years old than under 65 in ESBL-EC (2022: 0.289 vs 0.275) and non-ESBL-EC (2022: 0.103 vs 0.088).
Interpretation These findings, which show increasing MDR associations, especially in men and older individuals, highlight the importance of ongoing resistance surveillance to understand the future evolution of resistance patterns.
Funding This work received funding from the French government through the National Research Agency project COMBINE ANR–22-PAMR-0003.
Evidence before this study We searched Pubmed for previously published articles without any date or language restrictions using the search terms (multiresistan* OR “multidrug-resistan*”) AND (“data mining” OR “machine learning” OR “artificial intelligence”) AND (pattern* OR associat*). We found three studies that used machine learning to identify multiresistance patterns in various pathogens (chicken-associated Escherichia coli, human-associated Staphylococcus aureus and cattle-associated Salmonella enterica) in the United States. However, to our knowledge, no machine-learning studies to date have explored multiresistance patterns in human-associated Enterobacterales, especially within European contexts.
Added value of this study Our study provided a novel and detailed analysis of multiresistance patterns in community-acquired E. coli urinary tract infection collected from a French national surveillance system. Our findings confirmed that association-set mining is effective for identifying resistance associations in antibiotic resistance surveillance data. We explored the temporal evolution of resistance associations, gender-specific and age-specific differences, which to our knowledge, had not been previously analysed.
Implications of all the available evidence Our results suggest a temporal increase of resistance associations in community-acquired E. coli UTI and identify key patterns in different subpopulations. In the context of rising antibiotic resistance, optimizing the use of current medications is crucial, as few new antibiotics have been developed in the past two decades. With further research, this work could provide insight for targeted antibiotic stewardship strategies.
Competing Interest Statement
Dr Birgand reported receiving grants from Sante Publique France during the conduct of the study. No other disclosure was reported. Disclaimer: The views expressed are those of the authors and not necessarily those of Sante Publique France or the ANR.
Funding Statement
This work received funding from the French government through the National Research Agency project COMBINE ANR–22–PAMR–0003.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Because the analysis was performed using anonymized surveillance data, ethical consent was not required according to the French Data Protection Act. The dataset was accredited by the French National Data Protection Commission (CNIL 1,685,003), and the fully anonymized data waiver for informed consent of study participants was applied.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Members are listed in the Acknowledgements section
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of abbreviations
- AMR
- Antimicrobial-resistant
- AST
- Antibiotic susceptibility testing
- cLift
- conditional lift
- DDD
- defined daily dose
- ESBL-EC
- Extended-spectrum beta-lactamase producing E. coli
- eSup
- expected support
- MDR
- multidrug-resistant
- UTI
- urinary tract infection
